Nuron Biotech Selects the Merck BioManufacturing Network as Manufacturing Supplier for Next Generation Interferon Beta Pivotal Study for Multiple Sclerosis

Billingham, UK, February 8th 2011 – Nuron Biotech, Inc. has selected the Merck BioManufacturing Network in the UK to manufacture large scale GMP clinical supplies of NU100 and undertake process validation leading to long-term commercial operations. NU100 is a proprietary recombinant human interferon beta compound being developed for the treatment of multiple sclerosis (MS). Nuron Biotech plans to take NU100 into Phase III clinical trials in 2011. The manufacturing process uses a novel large scale pressure refold technology, PreEMT™, which has been installed on the Billingham, UK site.

“The novel steps in manufacturing that make NU100 unique are important to the success of our product development program,” stated Shankar Musunuri, PhD, MBA, Chief Executive Officer, Founder, Nuron Biotech. “The experience and breadth of capabilities offered by Merck BioManufacturing Network match our needs in both the clinical trial production as well as commercialization of our unique product for patients with MS.”

Steve Bagshaw, Site General Manager of the Merck BioManufacturing Network at Billingham, where NU100 will be manufactured, said, “We are delighted that Nuron has chosen to work with us, recognizing our many years of development experience in microbial biologics, our focus on introducing new technologies and our capacity that offers appropriate scales for their manufacturing needs.”

More than 2.1 million people worldwide are thought to be affected by MS, an inflammatory disease of the central nervous system that is often debilitating. Nuron believes that NU100 will be differentiated from other interferon-beta products by virtue of incorporation of PreEMT™ pressure enabled manufacturing process technology that creates a novel interferon beta-1b product that is both free of human serum albumin (HSA) and is essentially free of aggregates.
About Nuron Biotech

Nuron Biotech’s vision is to bring better biologics to market with enhanced product profiles for better health of patients. Nuron’s founders and management team are veteran industry executives who have made significant contributions in developing, launching and managing the life cycle of various biologics while at Pfizer and other biotechnology companies.

In less than a year after initiating operations Nuron has been extremely successful establishing late-stage product programs in three distinct disease areas, Central Nervous Systems (CNS), Wound Healing and Vaccines. www.nuronbiotech.com

About Merck BioManufacturing Network

Merck BioManufacturing Network (known outside the USA and Canada as MSD BioManufacturing Network) is a full service CMO providing development and manufacturing services for biologics to pharmaceutical and biotechnology companies. It comprises the operations at Billingham, UK (formerly Avecia Biologics), and at Research Triangle Park, NC, USA (formerly Diosynth Biotechnology). Merck is known as MSD outside USA and Canada. For additional information about Merck BioManufacturing Network, visit www.biomanufacturingnetwork.com.

PreEMT™ is a proprietary technology of BaroFold, Inc. and exclusively licensed to Nuron Biotech, Inc. for beta interferons.

Ends

For further information contact:

Bridget Hall
Communications Manager
MSD BioManufacturing Network
Billingham, UK
Tel : +44 (0)1642 367320

Richard C Dinovitz
VP Marketing & Business Development
Nuron Biotech
Exton, PA, USA
Tel : 610.968.6704
Forward-Looking Statement
This news release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company's plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation; the risk that the businesses will not be integrated successfully; disruption from the merger making it more difficult to maintain business and operational relationships; Merck's ability to accurately predict future market conditions; dependence on the effectiveness of Merck's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the U.S. and internationally and the exposure to litigation and/or regulatory actions. Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck's 2009 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov)